Annual Cash & Cash Equivalents
$206.18 M
+$90.77 M+78.65%
December 31, 2023
Summary
- As of February 7, 2025, VERV annual cash & cash equivalents is $206.18 million, with the most recent change of +$90.77 million (+78.65%) on December 31, 2023.
- During the last 3 years, VERV annual cash & cash equivalents has risen by +$197.19 million (+2192.67%).
- VERV annual cash & cash equivalents is now at all-time high.
Performance
VERV Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$158.71 M
+$17.22 M+12.17%
September 30, 2024
Summary
- As of February 7, 2025, VERV quarterly cash and cash equivalents is $158.71 million, with the most recent change of +$17.22 million (+12.17%) on September 30, 2024.
- Over the past year, VERV quarterly cash and cash equivalents has increased by +$80.34 million (+102.51%).
- VERV quarterly cash and cash equivalents is now -59.04% below its all-time high of $387.45 million, reached on June 30, 2021.
Performance
VERV Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
VERV Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +78.7% | +102.5% |
| 3 y3 years | +2192.7% | +102.5% |
| 5 y5 years | +6804.9% | +102.5% |
VERV Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +220.5% | -42.7% | +146.7% |
| 5 y | 5-year | at high | +6804.9% | -59.0% | +1664.8% |
| alltime | all time | at high | +6804.9% | -59.0% | +1664.8% |
Verve Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $158.71 M(+12.2%) |
| Jun 2024 | - | $141.49 M(-1.9%) |
| Mar 2024 | - | $144.20 M(-30.1%) |
| Dec 2023 | $206.18 M(+78.6%) | $206.18 M(+163.1%) |
| Sep 2023 | - | $78.37 M(+11.9%) |
| Jun 2023 | - | $70.04 M(-16.4%) |
| Mar 2023 | - | $83.75 M(-27.4%) |
| Dec 2022 | $115.41 M | $115.41 M(-58.3%) |
| Sep 2022 | - | $277.02 M(+280.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | $72.89 M(-20.3%) |
| Mar 2022 | - | $91.42 M(+42.1%) |
| Dec 2021 | $64.33 M(+615.3%) | $64.33 M(-56.6%) |
| Sep 2021 | - | $148.13 M(-61.8%) |
| Jun 2021 | - | $387.45 M(+289.8%) |
| Mar 2021 | - | $99.40 M(+1005.3%) |
| Dec 2020 | $8.99 M(+201.2%) | - |
| Dec 2020 | - | $8.99 M |
| Dec 2019 | $2.99 M | - |
FAQ
- What is Verve Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Verve Therapeutics?
- What is Verve Therapeutics annual cash & cash equivalents year-on-year change?
- What is Verve Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Verve Therapeutics?
- What is Verve Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Verve Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of VERV is $206.18 M
What is the all time high annual cash & cash equivalents for Verve Therapeutics?
Verve Therapeutics all-time high annual cash & cash equivalents is $206.18 M
What is Verve Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, VERV annual cash & cash equivalents has changed by +$90.77 M (+78.65%)
What is Verve Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of VERV is $158.71 M
What is the all time high quarterly cash and cash equivalents for Verve Therapeutics?
Verve Therapeutics all-time high quarterly cash and cash equivalents is $387.45 M
What is Verve Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, VERV quarterly cash and cash equivalents has changed by +$80.34 M (+102.51%)